» Articles » PMID: 21961471

Racial/Ethnic and Poverty Disparities in Human Papillomavirus Vaccination Completion

Overview
Journal Am J Prev Med
Specialty Public Health
Date 2011 Oct 4
PMID 21961471
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Two vaccines against human papillomavirus (HPV), a necessary cause of cervical cancer, are currently licensed and recommended for routine administration in the U.S. to girls in a three-dose series.

Purpose: This study examined effects of race/ethnicity, poverty, and year on completion of the three-dose HPV vaccine series among those who initiated vaccination.

Methods: Data from the 2008-2009 National Immunization Survey-Teen for girls aged 13-17 years who received at least one dose of HPV vaccine (n=7606) were analyzed in 2010-2011 using logistic regression to adjust for covariates including measures of access to care.

Results: During this 2-year period, 55% of adolescent girls who initiated vaccination completed the three-dose series. Completion was significantly higher in 2009 (60%) compared to 2008 (48%; p<0.001). After controlling for covariates, adolescents who were black (AOR=0.48, 95% CI=0.40, 0.57) or Hispanic (AOR=0.75, 95% CI=0.64, 0.88) were significantly less likely to complete vaccination than whites. Adolescents living below the federal poverty level were significantly less likely to complete vaccination than adolescents with household incomes >$75,000 (AOR=0.76, 95% CI=0.63, 0.92). There was no significant interaction between race/ethnicity and year (p=0.92). Although poverty was associated with lower completion rates in 2008, this association was not observed in 2009 (p<0.05 for poverty-year interaction).

Conclusions: HPV vaccination completion rates increased between 2008 and 2009. However, significant differences by race/ethnicity and poverty were observed, and the racial/ethnic differences persisted.

Citing Articles

Socioeconomic/health-related factors associated with HPV vaccination initiation/completion among females of paediatric age: A systematic review with meta-analysis.

Okoli G, Grossman Moon A, Soos A, Neilson C, Kimmel Supron H, Etsell K Public Health Pract (Oxf). 2025; 9():100562.

PMID: 39802391 PMC: 11721234. DOI: 10.1016/j.puhip.2024.100562.


Barriers to child vaccination: The role of international sanctions.

Ko J, Leung C, Lee H, Ming W SSM Popul Health. 2024; 28:101723.

PMID: 39554250 PMC: 11565545. DOI: 10.1016/j.ssmph.2024.101723.


Assessment of human papillomavirus vaccination rates of adolescents in California, 2018-2019.

Warren B, Gillette-Walch H, Adler J, Arias R, Klausner J, Ashing K Prev Med Rep. 2023; 32:102144.

PMID: 36852308 PMC: 9958035. DOI: 10.1016/j.pmedr.2023.102144.


Awareness of human papillomavirus and reported human papillomavirus vaccine uptake in a high-risk population.

Amboree T, Montealegre J, Padgett Wermuth P, Mgbere O, Fujimoto K, Darkoh C Prev Med Rep. 2022; 28:101853.

PMID: 35733608 PMC: 9207282. DOI: 10.1016/j.pmedr.2022.101853.


Social determinants of human papillomavirus vaccine series completion among U.S. adolescents: A mixed-methods study.

Mansfield L, Chung R, Silva S, Merwin E, Gonzalez-Guarda R SSM Popul Health. 2022; 18:101082.

PMID: 35493405 PMC: 9038569. DOI: 10.1016/j.ssmph.2022.101082.